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HYPOTHESIS
The influence of PFK-II overexpression 
on neuroblastoma patients’ survival may 
be dependent on the particular isoenzyme 
expressed, PFKFB3 or PFKFB4
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Abstract 
Background/Aim: During cancer progression metabolic reprogramming is observed in parallel to the alternation in 
transcriptional profiles of malignant cells. Recent studies suggest that metabolic isoenzymes of phosphofructokinase 
II (PFK‑II) – PFKFB3 and PFKFB4, often induced in hypoxic environment, significantly contribute to enhancement of 
glucose metabolism and in consequence cancer progression.
Materials and methods: Using the publicly available data deposited in the R2 data base we performed a Kaplan–
Meyer analysis for cancer patients divided into groups with high and low expression levels of PFKFB3/4, determined 
based on the median.
Results: Our data showed that high PFKFB3/4 expression significantly correlates with shorter overall survival in 
several cancers. Moreover, we found that neuroblastoma patients with poor overall survival and evidence free survival 
are characterized by high PFKFB3 and at the same time low PFKFB4 expression, whereas patients with high PFKFB4 
expressions are characterized by significantly better overall survival/evidence free survival rates.
Conclusion: Our analysis clearly indicates that expression of PFKFB3/4 isoenzymes may have a key prognostic value 
for several cancers. What’s more, it seems that in neuroblastoma the prognostic value of PFK‑II may be dependent on 
the relation between PFKFB3 and PFKFB4 isoenzyme expression, indicating that further studies analyzing the role of 
both cancer specific PFK‑II isoenzymes are highly desired.
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Background
Nowadays, the metabolic reprogramming of cancer cells 
is considered a very promising field for development of 
novel therapeutic strategies. Apparently, the most evi-
dent alterations in cancer metabolism are related to glu-
cose breakdown. As initially observed by Otto Warburg, 
in comparison to normal cells, the cancer cells ATP is 
generated mainly by glycolysis, even in normoxic con-
ditions [1, 2]. Although glycolysis is less efficient than 
oxidative phosphorylation, it allows the generation of 
ATP at a much faster pace, which is highly beneficial for 
proliferating cancer cells. Additionally, elevation of gly-
colysis enables sufficient production levels of glycolytic 
intermediates required for de novo nucleotide, lipid, 
amino acid, and NADPH synthesis. The role of enhanced 
glucose breakdown in carcinogenesis is well confirmed 
by studies, showing that attenuation of glycolysis inhib-
its growth and decreases survival of cancer cells [3, 4]. 
Without doubt, an attractive anti-cancer approach would 
be to target glycolysis by inhibiting the aforementioned 
enzymes crucial for this process. Nevertheless, to do so, 
there must be a significant difference in the particular 
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and normal proliferating cells. In fact, studies in recent 
years revealed that PFKFB3/PFKFB4 isoenzymes are 
excellent candidates for glycolysis targeting, especially in 
cancer cells [5, 6]. PFKFB3 and PFKFB4 are cancer spe-
cific isoenzymes of the bifunctional 6-phosphofructo-
2-kinase/fructose-2,6-bisphosphatase (PFKFB) enzyme 
group, responsible for controlling the steady-state cyto-
plasmic levels of fructose-2,6-bisphosphate, which allos-
terically activates phosphofructokinase-I (PFK-I), the key 
enzyme that catalyzes the rate-limiting step of glycoly-
sis [5, 7]. Several in vitro studies revealed that targeting 
PFKFB3 and PFKFB4 in cancer cells results in glycoly-
sis inhibition and in consequence, attenuation of tumor 
growth [8–12]. Without doubt, it is worth noting that 
PFKFB4 and PFKFB3 isoenzymes are not only involved 
in glucose metabolism but may also regulate other pro-
cesses crucial for carcinogenesis, having a multi-level 
anti-cancer effect [13–16]. Taking into consideration all 
of the aforementioned, and the fact that there is limited 
clinical data related to this topic, in our current paper, 
using publicly available data sets deposited in the R2 data 
base, we analyzed the influence of PFKFB3 and PFKFB4 
expression on overall survival of 49 independent, avail-
able cancer data sets. The results of the analysis indicates 
the importance of PFKFB3/4 co-expression for the clini-
cal outcome of cancer patients.
Materials and methods
R2 database
The R2 database (http://r2.amc.nl) is a simple to use web-
based genomics analysis and visualization application 
developed at the Department of Oncogenomics in the 
Academic Medical Center (AMC) in Amsterdam, Neth-
erlands [17]. It allows researchers to perform a range of 
analyses based on well annotated datasets. For the pur-
pose of this study we have chosen the Kaplan–Meier 
analysis of PFKFB3/PFKFB4 gene expression in the panel 
of cancer data sets. The gene expression cutoff value was 
chosen as a median over the entire dataset to ensure all 
analyses were based on the same cutoff.
Data validation and statistical analysis
For validation purposes the gene expression and sur-
vival data of 498 neuroblastoma patients (GSE62564) 
were downloaded from the NCBI Gene Expression 
Omnibus (GEO), a public repository of microarray data 
[18]. Based on the median expression level of PFKFB4 
and PFKFB3 genes, the patients were divided into four 
groups, namely: low PFKFB3/low PFKFB4 (G1), low 
PFKFB3/high PFKFB4 (G2), high PFKFB3/low PFKFB4 
(G3) and high PFKFB3/high PFKFB4 (G4) respectively, 
the survival curves were plotted using the Kaplan–Meier 
method and compared between each other using the 
log-rank test with Bonferroni correction (p value below 
0.05/6 was consider significant). Kaplan–Meyer analysis 
and univariate Cox proportional hazards regression were 
performed using GraphPad Prism 5.01 (GraphPad Soft-
ware, La Jolla, CA, USA).
Results
PFKFB3 and PFKFB4 expression‑based survival analysis 
in a panel of tumors using the R2 data base
Initially, using the R2 data base we analyzed the relation 
between PFKFB3 and PFKFB4 expression and the over-
all survival rate in the panel of cancers. The only crite-
rium for this analysis was availability of overall survival 
and expression data. The analyzed panel composed of 49 
data sets (Table 1), where some tumors were represented 
more than once. In every single data set, the patients 
were divided into two groups based on the median 
expression of PFKFB3 and/or PFKFB4. The difference 
in survival between these two groups was analyzed by a 
log rank test. Probability values below 0.05 were consid-
ered statistically significant and those between 0.05 and 
0.1 were marked as an indication of a trend. Our analysis 
revealed that in the case of Glioma and Liver hepatocel-
lular carcinoma patients with high PFKFB4 expression 
have significantly lower overall survival rates in compari-
son to patients with low expression of PFKFB4 (Table 1). 
As for PFKFB3, we have found that in kidney renal papil-
lary cell carcinoma patients high expression of this iso-
enzyme was significantly correlated with lower overall 
survivability. Interestingly, in cervical squamous cell car-
cinoma we revealed that patients with high expression of 
both, PFKFB3 and PFKFB4 have significantly worse over-
all survival in comparison to the ones with low expres-
sion. Although the overexpressed PFKFB3/4 isoenzymes 
are considered oncogenic, mantle cell lymphoma, ovarian 
and pancreatic adenocarcinoma data sets have revealed 
that patients with low expression of PFKFB3 enzyme 
have significantly worse survival rates in comparison to 
the ones with high expression (Table 1).
Analysis of the relation between PFKFB3 and PFKFB4 
expression in neuroblastoma patients
Without doubt, the most interesting data was obtained 
through neuroblastoma data sets. Surprisingly, in two 
independent cohorts we observed that high expres-
sion of PFKFB3 negatively influences the overall sur-
vival, whereas in five independent data sets patients 
with high expression of PFKFB4 had significantly bet-
ter OS (Table  1). In order to determine the influence 
of PFKFB3/4 co-expression on survival rate, the gene 
expression data were downloaded (GSE62564) and neu-
roblastoma patients were divided on four groups based 
on the median PFKFB3/PFKFB4 expression (Fig.  1), as 
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Table 1 Analysis of  the  relation between  PFKFB3 and  PFKFB4 expression and  the  overall survival rate in  the  panel 
of cancers
Cancer type Patient number Source P value for PFKFB3 P value for PFKFB4
Acute myeloid leukemia 422 GEO ID:GSE37642 0.713 0.704
Adrenocortical carcinoma 79 TCGA ID:ND 0.083a 0.076a
B‑cell lymphoma 414 GEO ID:GSE10846 0.069b 0.528
Bladder urothelial carcinoma 224 GEO ID:GSE32894 0.508 0.331
Bladder urothelial carcinoma 408 TCGA ID:BLCA 0.555 0.352
Breast 159 GEO ID:GSE1456 0.405 0.110
Breast 130 GEO ID:GSE69031 0.527 0.913
Breast invasive carcinoma 1096 TCGA ID:BRCA 0.358 0.858
Cervical squamous cell carcinoma 292 TCGA ID:CESC 0.032a 0.026a
Cholangiocarcinoma 36 TCGA ID:CHOL 0.859 0.402
Colon 200 GEO ID:GSE17538 0.041a 0.775
Esophageal adenocarcinomas 70 GEO ID:GSE19417 0.854 0.098b
Esophageal carcinoma 183 TCGA ID:ESCA 0.814 0.384
Ewing sarcoma 85 GEO ID:GSE63157 0.073a 0.094a
Glioblastoma 80 GEO ID:GSE7696 1.000 1.000
Glioblastoma 377 ND ID:ND 0.525 0.286
Glioblastoma 504 ND ID:ND 0.964 0.387
Glioma 490 GEO ID:GSE108474 0.378 1.2e−09a
Glioma 273 GEO ID:GSE16011 0.129 1.4e−10a
Glioma 50 GEO ID:GSE43378 0.730 0.028a
Glioma pediatric 47 GEO ID:GSE19578 0.092a 0.625
Intrinsic glioma subtypes 95 GEO ID:GSE43107 0.069b 0.660
Head neck squamous cell carcinoma 520 TCGA ID:HNSC 0.640 0.875
Kidney renal clear cell carcinoma 533 TCGA ID:KIRC 0.464 0.542
Kidney renal papillary cell carcinoma 290 TCGA ID:KIRP 0.012a 0.064a
Liver hepatocellular carcinoma 371 TCGA ID:LIHC 0.058a 6.6e−05a
Lung 106 GEO ID:GSE3141 0.819 0.100a
Lung adenocarcinoma 515 TCGA ID:LUAD 0.814 0.961
Tumor lymphoma 162 GEO ID:GSE58445 0.315 0.486
Tumor lymphoma 470 GEO ID:GSE31312 0.431 0.555
Mantle cell lymphoma 122 GEO ID:GSE93291 0.030b 0.070a
Medulloblastoma 612 GEO ID:GSE85217 0.576 0.720
Melanoma 214 GEO ID:GSE65904 0.633 0.048a
Metastatic melanoma 44 GEO ID:GSE19234 0.558 0.394
Myeloma 542 GEO ID:GSE2658 0.078b 0.514
Neuroblastoma 476 GEO ID:GSE45547 1.8e−04a 6.2e−04b
Neuroblastoma 498 GEO ID:GSE62564 6.8e−04a 1.6e−06b
Neuroblastoma stage IV 27 GEO ID:GSE79910 0.939 0.325
Neuroblastoma primary 283 GEO ID:GSE85047 0.090a 3.3e−03b
Neuroblastoma 247 ND ID:ND 0.272 6.1e−03b
Neuroblastoma 88 GEO ID:GSE16476 0.398 0.078b
Ovarian 75 GEO ID:GSE63885 3.9e−03b 0.941
Ovarian adenocarcinoma 107 GEO ID:GSE26193 0.371 0.302
Pancreatic subtypes 96 ND ID:ND 0.070a 0.058a
Pancreatic adenocarcinoma 146 TCGA ID:PAAD 0.016b 0.928
Pancreatic ductal adenocarcinoma 102 GEO ID:GSE21501 0.615 0.598
Skin cutaneous melanoma 468 TCGA ID:SKCM 0.192 0.493
Stomach adenocarcinoma 415 TCGA ID:STAD 0.218 0.738
Thymoma 120 TCGA ID:THYM 0.952 0.113
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described in Materials and Methods. As determined in 
Fig.  2, our analysis clearly indicates that patients with 
high PFKFB4 expression (G2 and G4 groups) have a sig-
nificantly better overall survival, which might suggest 
that regardless of the PFKFB3 level of expression (high in 
G4 group and low in G2), PFKFB4 has a positive impact 
on the patients survival rate. The worst survival progno-
sis could be observed for the patients with the dominant 
PFKFB3 expression (G3 group), which clearly indicates 
that low expression of PFKFB4, and high expression of 
PFKFB3 at the same time has a negative impact on the 
survival of neuroblastoma patients. Importantly, the 
same correlation was observed for evidence free survival. 
This suggests that if the high expression of the PFKFB3 
isoenzyme is not balanced by the expression of PFKFB4, 
then the patients show much worse survival rate. Sub-
group analysis was further extended, and univariate 
Cox proportional hazards regression was performed. As 
determined in Fig. 2 lower panel, there is a better over-
all survival and evidence free survival rate in the group of 
patients with dominant PFKFB4 (G2 group) in compari-
son to the group of patients with dominant PFKFB3 (G3 
group), with hazard rates of 0.26 and 0.39 respectively. 
What is more, group G3 presented worse overall survival 
and evidence free survival in comparison to the G4 group 
(high PFKFB3/high PFKFB4), with hazard ratios of 2.56 
and 1.69 respectively, which indicates that negative 
impact of PFKFB3 expression can be offset by the expres-
sion of PFKFB4.
Discussion
Currently, several literature data indicates PFK-II as a 
potential marker of cancer prognosis [19–25]. Never-
theless, up to this day, most research on PFK-II refers 
to one of the two cancer specific isoenzymes PFKFB3 
or PFKFB4 [8–12, 19, 20, 22–25], undoubtedly neglect-
ing the importance of co-expression of individual iso-
enzymes. Our analysis of publicly available data sets 
unquestionably indicates that in several tumors, high 
PFKFB3 and/or PFKFB4 expression correlates with poor 
survivability. Importantly, our analysis confirmed the 
previously published negative impact of PFKFB4 on the 
prognosis of glioma patients [23] and negative impact of 
PFKFB3 on the prognosis of hepatocellular cancer [24]. 
Interestingly, recently published data also revealed the 
negative impact of PFKFB4 on breast and bladder can-
cer patients but it was not noticable in the data sets we 
have analyzed. Nevertheless, Li et al. [22] and Ling et al. 
[20] analyzed the expression of PFKFB3 and PFKFB4 at 
the protein level in lung and breast cancer, which defi-
nitely may explain the discrepancy between the out-
comes. Moreover, it may suggest that the same analysis, 
as we have done so far, could be performed at the pro-
tein level revealing more tumors for which expression of 
PFKFB3/PFKFB4 constitutes a potent prognostic marker. 
Undoubtedly, attention should be paid to the fact that in 
the case of neuroblastoma solely high expression of iso-
enzyme PFKFB3 correlates with poor prognosis whereas 
solely high expression of PFKFB4 is a positive prognos-
tic factor for these patients. According to our current 
knowledge, there is no single study analyzing the influ-
ence of PFK-II on neuroblastoma patients’ prognosis, 
whereas our analysis clearly indicates that cancer specific 
isoenzymes may have opposite effects on prognosis in 
this group of specific cancer patients.
Although both genes code for phosphofructokinase II, 
according to the literature, kinase activity dominates in 
the PFKFB3 isoenzyme [26, 27], enhancing the glycolytic 
breakdown of glucose, whereas PFKFB4 seems to have 
higher FBPase-2 activity [5, 28], stimulating the flow of 
Table 1 (continued)
Bold italic indicates the p value below 0.05
italic indicates the p value between 0.05 and 0.1
ND no data
a High is worse























Fig. 1 Analysis of PFKFB3 and PFKFB4 mRNA expression in 
neuroblastoma patients using a publicly available data set GSE62564. 
498 neuroblastoma patients were classified in accordance to their 
PFKFB3 and PFKFB4 mRNA expression. The patients were divided 
into four expression groups (G1—low PFKFB3/low PFKFB4, G2—
low‑PFKFB3/highPFKFB4, G3—high PFKFB3/low PFKFB4, G4—high 
PFKFB3/high PFKFB4) based on the median
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glucose toward the pentose phosphate pathway, provid-
ing the source of NADPH, crucial as a reducing factor for 
lipid biosynthesis and ROS-detoxifying enzymes. Alto-
gether, we speculate, that the group with high PFKFB3 
expression and low PFKFB4 may be characterized by 
higher glycolysis rates in relation to other groups whereas 
the PFKFB4 solely high group will have the lower glyco-
lytic activity in comparison to other patients. If PFKFB3 
dependent glycolytic cell activity in neuroblastoma 
indeed has significant impact on neuroblastoma cell pro-
liferation [29], as determined by Almeida et al., one would 
expect to have opposite effects of PFKFB3 and PFKFB4 
expression on patient survival as observed in our study. 
In addition, the analysis of the impact of isoenzymes 
on patients’ survival rates should also take into account 
that both, PFKFB3 and PFKFB4 are vastly involved in 
other important biological processes in a non-glycoly-
sis-dependent manner [13–16, 30–32], which could also 
explain their opposite effect on neuroblastoma patients’ 
prognosing. For instance, it has been shown that PFKFB3 
can be localized in the nucleus, which results in prolif-
eration enhancement without increasing of the glycolytic 
rate. As reported by Yalcin et al. both, kinase activity of 
PFKFB3 and nuclear localization are needed for its effect 
on cancer cell proliferation [32]. As for PFKFB4, it has 
been reported that this enzyme is somewhat involved, 
be it directly or indirectly, in phosphorylation of the 
CBP-interacting domain of oncogenic steroid recep-
tor coactivator-3 (SRC-3), enhancing its transcriptional 
activity, which results in higher expression of its target 
genes; transketolase, adenosine monophosphate deami-
nase-1 (AMPD1) and xanthine dehydrogenase (XDH), 
involved in the metabolism of nucleotides [13]. Regard-
less of the molecular mechanism of action of PFKFB3/4 
isoenzymes our data clearly indicates that in analyzing 
the effect of PFK-II on the prognosis of cancer patients, 
the expression of both PFKFB3/4 isozymes should be 
considered. This is particularly important in the case of 
potential use of PFK-II inhibitors, because, as our analy-
sis has undoubtedly shown, the effectiveness of inhibition 
may be dependent on the suitable inhibitor application 
for a specific isoenzyme overexpressed in specific can-
cer cells. What is more, our analysis indicates worryingly, 
that application of PFKFB4 inhibitors for neuroblastoma 
Fig. 2 PFKFB3/PFKFB4 expression profile influences the prognosis of neuroblastoma patients. Upper panel: The publicly available data set 
GSE62564 was used to analyze the overall survival and evidence free survival in four expression groups G1, G2, G3, G4. Kaplan–Meier curves are 
presents for overall survival and evidence free survival. Lower panel: Survival curves comparison using the log‑rank test with Bonferroni correction 
(p value below 0.0083 was considered significant). Univariate hazard ratios with confidence intervals were obtained by Cox regression analysis
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patients characterized by overexpression of both isoen-
zymes could even have a negative impact on the patient 
prognosis. Consequently, the results of our analysis pro-
vide important insight for future clinical oncology by pre-
senting the importance of metabolic enzymes as a likely 
destination for modern targeted anti-tumor therapy.
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